Amita Saggi, PA
Physician Assistant · Pleasanton, CANPI 1346580503
Payments from drug & device makers
Across 76 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$428
- Pfizer$261
- AstraZeneca$125
- Amgen$124
- Takeda Pharmaceuticals U.S.A., Inc.$123
- Merck$118
- plus $603 from 17 others
What the payments were for
- Food & beverage$1,48783%
- Education$29417%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 20 | $428 |
| Pfizer | 16 | $261 |
| AstraZeneca | 1 | $125 |
| Amgen | 4 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| Merck | 4 | $118 |
| E.r. Squibb & Sons, L.L.C. | 4 | $96 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $69 |
| Gilead | 3 | $68 |
| Johnson & Johnson | 2 | $60 |
| Eisai Inc. | 2 | $42 |
| GSK | 1 | $35 |
| Rigel Pharmaceuticals, Inc. | 1 | $29 |
| AbbVie | 1 | $28 |
| Bristol Myers Squibb | 1 | $26 |
| Teleflex LLC | 1 | $25 |
| Beigene USA, Inc. | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Novartis | 1 | $17 |
| Coherus Oncology, Inc. | 1 | $16 |
| Novocure Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$125
How this compares
$1,782 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 33 | $647,567 |
| Abiraterone Acetate | 152 | $586,934 |
| RevlimidLenalidomide | 34 | $534,428 |
| BrukinsaZanubrutinib | 30 | $454,300 |
| TagrissoOsimertinib Mesylate | 19 | $327,112 |
| WeliregBelzutifan | 11 | $262,206 |
| LynparzaOlaparib | 18 | $223,340 |
| ImbruvicaIbrutinib | 13 | $188,008 |
| Lenalidomide | 20 | $187,155 |
| NinlaroIxazomib Citrate | 12 | $151,424 |
| XareltoRivaroxaban | 60 | $77,156 |
| EliquisApixaban | 47 | $35,658 |
| Imatinib Mesylate | 13 | $10,602 |
| Letrozole | 100 | $2,876 |
| Hydroxyurea | 30 | $662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $17 | $647,56733 claims |
| AstraZenecaTagrisso, Lynparza | $125 | $550,45137 claims |
| Bristol Myers SquibbRevlimid | $26 | $534,42834 claims |
| Beigene USA, Inc.Brukinsa | $21 | $454,30030 claims |
| MerckWelireg | $118 | $262,20611 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $69 | $188,00813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $123 | $151,42412 claims |
| Johnson & JohnsonXarelto | $60 | $77,15660 claims |
| PfizerEliquis | $261 | $35,65847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Pleasanton
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Eric CheungLos Angeles$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.